Shares in US gene therapy specialist Rocket Pharmaceuticals (Nasdaq: RCKT) rose by 9% in the opening 90 minutes of trading on Monday.
The stock market was reacting to news that Rocket had signed a deal with biotech company Regenxbio, which also opened higher at the start of the week’s trading.
This exclusive, worldwide license agreement will see Rocket develop and commercialize gene therapies for Danon disease using Regenxbio's NAV AAV9 vector, and acquire exclusive options for two additional NAV AAV vectors for the treatment of the rare neuromuscular and cardiovascular condition.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze